Risk Factors Determining Chemotherapeutic Toxicity in Patients with Advanced Colorectal Cancer
暂无分享,去创建一个
D. Sleijfer | J. Brouwers | Jacobus R.B.J. Brouwers | Frank G.A. Jansman | Dirk T. Sleijfer | Jules L.L.M. Coenen | Jacques C. Graaf | F. Jansman | J. C. Graaf | J. Coenen
[1] F. D. Boudinot,et al. Age-Related Changes in Protein Binding of Drugs , 2000, Clinical pharmacokinetics.
[2] H. Wieand,et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Fukuoka,et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. Lévi,et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.
[5] J. Gutterman,et al. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Culine,et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] C. Ardiet,et al. Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. , 1997, Cancer treatment reviews.
[8] Caen,et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] R. Petrioli,et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. , 1995, European journal of cancer.
[10] J. Lotz,et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.
[11] R. Rosso,et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. , 1997, European journal of cancer.
[12] M. Buyse,et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Tournigand,et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.
[14] A. Favero,et al. Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Ratain,et al. Individualizing dosing of cancer chemotherapy. , 1993, Seminars in oncology.
[16] M. Ratain. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Fountzilas,et al. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] E. Van Cutsem,et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). , 1999, European journal of cancer.
[19] W. Scheithauer,et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Hiddemann,et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] F. Demard,et al. No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. , 1992, British Journal of Cancer.
[22] B. van Triest,et al. Current chemotherapeutic possibilities in the treatment of colorectal cancer. , 1995, European journal of cancer.
[23] R. Diasio,et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. , 1990, Cancer research.
[24] D. Kerr,et al. Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. , 1988, British Journal of Cancer.
[25] G. Chabot. Clinical Pharmacokinetics of Irinotecan , 1997, Clinical pharmacokinetics.
[26] F. Lévi,et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.
[27] S. Groshen,et al. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. , 1993, Journal of the National Cancer Institute.
[28] H. Wieand,et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] L. Grochow,et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. , 1994, Cancer research.
[30] N. Petrelli,et al. Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial , 1995, Cancer.
[31] H. Rauschecker,et al. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] G Milano,et al. © 1999 Cancer Research Campaign Article no. bjoc.1998.0098 Dihydropyrimidine dehydrogenase deficiency and , 2022 .
[33] E. Gamelin,et al. Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.
[34] I. Seymour,et al. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] F. Naguib,et al. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. , 1994, Cancer research.
[36] P. Hérait,et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Michael C. Brown. Multisite Mucous Membrane Bleeding Due to a Possible Interaction Between Warfarin and 5‐Fluorouracil , 1997, Pharmacotherapy.
[38] J. Lotz,et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.
[39] M. Ychou,et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] O. Dassonville,et al. [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.
[41] F. Lévi,et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.
[42] C. Erlichman,et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. , 1992, European journal of cancer.
[43] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Ychou,et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] N. Petrelli,et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] R. Herrmann,et al. Pharmacokinetics of 5‐Fluorouracil After Short Systemic Infusion: Plasma Level at the End of the Distribution Phase as an Indicator of the Total Area Under the Plasma Concentration‐Time Curve , 1991, Therapeutic drug monitoring.
[47] R. Diasio,et al. Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome , 1991, Cancer.
[48] M. Ducreux,et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] J. Robert,et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[50] R. Tang,et al. A simplified regimen of weekly high dose 5‐fluorouracil and leucovorin as a 24‐hour infusion in patients with advanced colorectal carcinoma , 1999, Cancer.
[51] Michael R. Green,et al. The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial , 1990 .
[52] D. Kerr,et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] A. de Gramont,et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. , 1988, European journal of cancer & clinical oncology.
[54] H. Pinedo,et al. Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] M. Bibby,et al. Pharmacokinetic Drug Interactions with Anticancer Drugs , 1994, Clinical pharmacokinetics.
[56] F. Goldwasser,et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] J. Robert,et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] M. O’connell. A phase III trial of 5‐fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study , 1989, Cancer.
[59] D. V. Von Hoff,et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] J. Sludden,et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. , 1998, British Journal of Cancer.
[61] O. Drummer,et al. Fluorouracil Therapy in Patients with Carcinoma of the Large Bowel: A Pharmacokinetic Comparison of Various Rates and Routes of Administration , 1978, Clinical pharmacokinetics.
[62] E. Van Cutsem,et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] S. Culine,et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. , 1994, Cancer research.
[64] D. Kerr,et al. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. , 1998, European journal of cancer.
[65] J. Misset,et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function , 2000, Cancer Chemotherapy and Pharmacology.
[66] J. Michaelis,et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] D. Kerr,et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] F. Goldwasser,et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] M. Fukuoka,et al. Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin , 1995, Japanese journal of cancer research : Gann.
[70] D. V. Von Hoff,et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] S. Howell,et al. Modulation of 5‐fluorouracil toxicity by allopurinol in man , 1981, Cancer.
[72] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[73] T. Fleming,et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] H. Gurney,et al. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] E. Raymond,et al. Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] F. Lévi,et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma , 1999, Cancer.
[77] A. Gouyette,et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[78] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[79] L. Grochow,et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] Y. Rustum,et al. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. , 1982, Cancer research.
[81] G. Peters,et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. , 1988, Cancer research.
[82] S. Culine,et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] O. Dassonville,et al. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] M. Seymour,et al. Colorectal cancer: treatment of advanced disease. , 1998, Cancer treatment reviews.
[85] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[86] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] D. Morgan,et al. Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.
[88] R. Labianca,et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[89] M. Ratain,et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] R. Herrmann,et al. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. , 1991, Oncology.
[91] F. Lévi,et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] J. Fourtillan,et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] J. Dierlamm,et al. Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma. , 1994, European journal of cancer.
[94] P. Beale,et al. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694). , 1998, British Journal of Cancer.
[95] M. Marty,et al. Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.
[96] M. Slevin,et al. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. , 1984, British journal of clinical pharmacology.
[97] F. Lévi,et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. , 1988, Cancer research.
[98] K. Eguchi,et al. A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38 , 1995, Japanese journal of cancer research : Gann.
[99] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[100] S. Iacobelli,et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.
[101] M. Ratain,et al. Pharmacogenetics in cancer etiology and chemotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[102] J. Hainsworth,et al. A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma , 1999, Cancer.
[103] D. Machover. A comprehensive review of 5‐fluorouracil and leucovorin in patients with metastatic colorectal carcinoma , 1997, Cancer.
[104] R. Labianca,et al. Errata: Treatment of colorectal cancer: Current guidelines and future prospects for drug therapy (Drugs (1997) 53 (593-607)) , 1997 .
[105] M. Ratain,et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital , 1997, Cancer Chemotherapy and Pharmacology.
[106] H. Bleiberg. Colorectal cancer--is there an alternative to 5-FU? , 1997, European journal of cancer.
[107] N. Petrelli,et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] B. Desoize,et al. Individual dose adaptation of anticancer drugs. , 1994, European journal of cancer.
[109] J. Laurie,et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] C. Tournigand,et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[111] A. Rubagotti,et al. Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. , 1992, European journal of cancer.
[112] M. Ratain,et al. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. , 1996, Cancer research.
[113] M. Namer,et al. Dose Versus pharmacokinetics for predicting tolerance to 5‐day continuous infusion of 5‐FU , 1988, International journal of cancer.
[114] P. Woolley,et al. A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[116] C. Peterson,et al. Pharmacokinetic Optimisation of Anticancer Therapy , 1991, Clinical pharmacokinetics.
[117] H. Sumiyoshi. Clinical pharmacological evaluation of CPT-11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) , 1995 .
[118] J. Sloan,et al. Sex differences in fluorouracil-induced stomatitis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] J. Willson,et al. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] M. Vincent,et al. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. , 1998, Oral oncology.
[121] G Milano,et al. Spontaneous or imposed circadian changes in plasma concentrations of 5‐fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer , 1994, Clinical pharmacology and therapeutics.
[122] E. Tian,et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[123] F. Demard,et al. Influence of sex and age on fluorouracil clearance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[125] S. Barni,et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients , 1997, Supportive Care in Cancer.
[126] O. Bouché,et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] M. Ratain,et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[128] F. Demard,et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. , 1989, British Journal of Cancer.
[129] P. Hérait,et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] J. Schornagel,et al. Clinical pharmacokinetics of anti-metabolites. , 1993, Cancer surveys.